• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20010 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Bulevirtide (chronic hepatitis delta virus (HDV) infection)]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belantamab mafodotin (multiple myeloma) - Addendum to Commission G20-22]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the update of the DMP "Breast cancer"]
2021     NIHR Health Technology Assessment programme Estimating the benefits and harms of Z-drugs for people with dementia and sleep disorders
2021     The Federal Joint Committee (G-BA) [Pharmaceuticals Directive/Annex XII: Burosumab (new therapeutic indication: X-linked hypophosphataemia, ≥ 18 years)]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Amikacin sulfate (Mycobacterium avium Complex [MAC] lung infections) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Crizanlizumab (sickle cell disease) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Afamelanotide (Reassessment after the deadline: Phototoxicity in erythropoietic protoporphyria (EPP))]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guselkumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme ROCkeTS - Refining Ovarian Cancer Test Accuracy Scores
2021     NIHR Health Technology Assessment programme A randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression.
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tafamidis (transthyretin amyloidosis) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tafamidis (transthyretin amyloidosis with cardiomyopathy) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme Preventing enduring behavioural problems in young children through early psychological intervention: Healthy Start, Happy Start
2021     NIHR Health Technology Assessment programme A multi-centre cluster randomised controlled trial to evaluate the Guide to Action Care Home fall prevention programme in care homes for older people (FinCH)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 4 to < 6 months, with R117H mutation) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme Investigating the effectiveness and cost effectiveness of using FITNET to treat paediatric CFS/ME in the UK
2021     Norwegian Institute of Public Health (NIPH) Minimally invasive glaucoma surgery (MIGS) for individuals with glaucoma. A health technology assessment
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (cystic fibrosis, 4 to < 6 months, gating mutation) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme Statin Web-based Investigation of Side Effects Trial (Statin WISE Trial)
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating diagnostic measures in a person with signs and symptoms suggestive of a urinary tract infection (cystitis or pyelonephritis) and initiating first-line pharmacological treatment for cystitis in an adult with functional autonomy decline]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tezacaftor/ivacaftor (combination with ivacaftor; cystic fibrosis, 6 to < 12 years, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme Prognostic indicators of severe disEAse in women with late preterm pre-eClampsia tO guide deCision-maKing on timing of delivery (PEACOCK study)
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: urinary catheter placement in an adult with functional autonomy decline presenting with symptoms suggestive of acute urinary retention]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Fenfluramine (Dravet syndrome, ≥ 2 years)]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with tezacaftor/ivacaftor; cystic fibrosis, 6 to < 12 years, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme A randomised controlled trial comparing the clinical effectiveness and cost-effectiveness of laparoscopic cholecystectomy compared with observation/conservative management for preventing recurrent symptoms and complications in adults with uncomplicated symptomatic gallstones (C-Gall)
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating blood work for the purpose of evaluating diagnosed or suspected alcohol use disorder]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tezacaftor/ivacaftor (combination with ivacaftor; cystic fibrosis, 6 to < 12 years, F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme A randomized controlled trial to study the effectiveness of laser ablation versus observation to prevent anal cancer in men with human immunodeficiency virus who have high-grade anal intraepithelial neoplasia
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating pharmacotherapy for relapse prevention in a person with alcohol use disorder]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with tezacaftor/ivacaftor; cystic fibrosis, 6 to < 12 years, F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: efficacy and safety of pharmacological treatments for alcohol withdrawal and relapse prevention]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Glasdegib (acute myeloid leukaemia (AML), combination with cytarabine (LDAC))]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Niraparib (first-line maintenance treatment in advanced ovarian cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: administration of benzodiazepines or gabapentin prescribed via an individual prescription for alcohol withdrawal]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nusinersen (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V]
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Imlifidase (desensitisation in kidney transplantation)]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a stent graft with a valve component for tricuspid regurgitation - Assessment according to §137h Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Percutaneously implanted interatrial shunt for the treatment of heart failure - Assessment according to §137h Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Coronary lithoplasty for coronary heart disease - Assessment according to §137h Social Code Book V]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Fear of childbirth, depression and anxiety during pregnancy]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selection of interventions for the "second opinion" procedure according to § 27b Social Code Book V - Rapid Report]
2021     NIHR Health Services and Delivery Research programme Clinical and cost effectiveness of progressive exercise compared to best practice advice, with or without corticosteroid injection, for the treatment of rotator cuff disorders: a 2x2 factorial randomised controlled trial (The GRASP trial)
2021     Norwegian Institute of Public Health (NIPH) [Evaluation of PD-L1 assays in urothelial carcinoma: a rapid HTA]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sucroferric oxyhydroxide (hyperphosphataemia in children and adolescents 2 years of age and older with CKD stages 4-5 or with CKD on dialysis) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme ALternative To prophylactic Antibiotics for the treatment of Recurrent urinary tract infections in women (ALTAR study)
2021     NIHR Public Health Research (PHR) programme The VIP trial: a randomised controlled trial of the clinical and cost effectiveness of a Victim Improvement Package (VIP) for the reduction of chronic symptoms of depression or anxiety in older victims of common crime
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of single-photon emission computed tomography with [ 123I]ioflupane (DaTscan) in the diagnostic process for parkinsonian syndromes]
2021     Malaysian Health Technology Assessment (MaHTAS) Hyperthermic intraperitoneal chemotherapy as an adjuvant therapy for peritoneal surface malignancy (PSM)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sebelipase alfa (lysosomal acid lipase deficiency) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     NIHR Health Technology Assessment programme A multi-centre randomised controlled trial to compare the clinical and cost effectiveness of Lee Silverman Voice Treatment versus standard NHS speech and language therapy versus control in Parkinson's disease (PD COMM)
2021     NIHR Public Health Research (PHR) programme Does slip resistant footwear reduce slips among healthcare workers? A randomised controlled trial
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of neonatal pulse oximetry screening for critical congenital heart disease]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (chronic lymphocytic leukaemia; pretreated) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme How do smoking cessation medicines compare with respect to their neuropsychiatric safety: a systematic review, network meta-analysis and cost effectiveness analysis.
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: mammographic density and breast cancer screening]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme OPTIMA: Optimal Personalised Treatment of early breast cancer usIng Multi-parameter Analysis
2021     Swiss Federal Office of Public Health (FOPH) Long-term physiotherapy in patients after stroke, with multiple sclerosis, or with Parkinson’s disease
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ipilimumab (non-small cell lung cancer, combination with nivolumab) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Public Health Research (PHR) programme The impact of a family-based physical activity promotion programme on child physical activity: feasibility and pilot of the Families Reporting Every Step to Health (FRESH) intervention.
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (non-small cell lung cancer, combination with ipilimumab) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Services and Delivery Research programme Accounting for multimorbidity, competing risk and direct treatment disutility in risk prediction tools and model-based cost-effectiveness analysis for the primary prevention of cardiovascular disease and osteoporotic fracture
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Public Health Research (PHR) programme RISKIT-CJS Pragmatic randomized controlled trial to evaluate the effectiveness and cost-effectiveness of a multi-component intervention to reduce substance use and risk-behaviour in adolescents engaged with the criminal justice system
2021     National Authority for Assessment and Accreditation in Healthcare (INEAS) ZELBORAF® (vemurafenib) en monothérapie dans le traitement du mélanome non résécable ou métastatique à mutation BRAF V600
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Public Health Research (PHR) programme Evaluating graduated progress towards and impacts of the implementation of indoor smoke free prison facilities in Scotland
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (chronic lymphocytic leukaemia; combination with obinutuzumab) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme Improving the Wellbeing of people with Opioid Treated CHronic pain; I-WOTCH
2021     Scottish Health Technologies Group (SHTG) HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Luspatercept (β-thalassaemia)]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (adenocarcinoma of the pancreas) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel (partial-onset seizures) - Benefit assessment according to §35a Social Code Book V]
2021     Austrian Institute for Health Technology Assessment (AIHTA) [Sponsoring of patient initiatives in Austria. Update of the systematic analyses 2014 to 2018]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel (generalized epilepsy) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (small cell lung cancer) - Addendum to Commission A20-87]
2021     NIHR Health Technology Assessment programme A Phase II randomised clinical trial of conditioning cyclophosphamide and chemoembolisation with or without vaccination with dendritic cells pulsed with HepG2 lysate ex vivo in patients with Hepatocellular Carcinoma: IMMUNOTACE
2021     NIHR Health Technology Assessment programme The cystic fibrosis (CF) anti-staphylococcal antibiotic prophylaxis trial (CF START); a randomised registry trial to assess the safety and efficacy of flucloxacillin as a longterm prophylaxis agent for infants with CF
2021     Austrian Institute for Health Technology Assessment (AIHTA) [Epidemiology of long COVID: a preliminary report. German short version of the original KCE report]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (small cell lung cancer) - Addendum to Commission A20-87]
2021     Austrian Institute for Health Technology Assessment (AIHTA) Implantation of bulking agents for faecal incontinence. Update 2021: systematic review
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Cognitive training / cognitive stimulation]
2021     Austrian Institute for Health Technology Assessment (AIHTA) Percutaneous left ventricular assist devices: micro-axial flow pumps: systematic review
2021     Canary Health Service [Framework for relations between the Spanish Network of HTA agencies of the NHS with industry]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Afamelanotide (erythropoietic protoporphyria) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2021     Austrian Institute for Health Technology Assessment (AIHTA) Liposuction for surgical therapy of lipoedema: systematic review
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lumasiran (hyperoxaluria) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: assessment and risk management of severe neurological complications following mild traumatic brain injury]
2021     Austrian Institute for Health Technology Assessment (AIHTA) Triphasic biomaterial for augmentation of the osteoporotic femoral neck: systematic review
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Semaglutide (type 2 diabetes mellitus) - Addendum to Commission A20-93]
2021     NIHR Health Technology Assessment programme Adrenaline to improve survival in out-of-hospital cardiac arrest: the PARAMEDIC2 RCT
2021     Austrian Institute for Health Technology Assessment (AIHTA) Endoscopic plication therapy in patients with gastroesophageal reflux disease (GERD): systematic review
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Austrian Institute for Health Technology Assessment (AIHTA) Allogenic bone screw Shark Screw® in patients with hallux valgus or scaphoid fractures/pseudarthroses: systematic review
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis in children) - Benefit assessment according to §35a Social Code Book V]
2021     Austrian Institute for Health Technology Assessment (AIHTA) (Good) practice organisational models using real-world evidence for public funding of high priced therapies
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]